Harpenden, UK, 24 September 2019: St George Street Capital (SGSC), a UK registered charity, has signed a license agreement with AstraZeneca to develop two compounds in the clinic: one for idiopathic male infertility, and the other for renal transplant rejection. The agreement enables additional compounds to be added in the future.
News
Aston Particle Technologies (APT) has significantly expanded its in-house R&D capabilities by investing in two benchtop systems – designed by Ely-based GB Innomech (Innomech) – to prepare small quantities of blended pharmaceutical powders for use in its formulation development projects for pharmaceutical companies.
Global Regulatory Services (GRS) spins out new Irish Consultancy, Med-Di-Dia, to focus on EU MedTech
GRS spins out new Irish Consultancy, Med-Di-Dia (www.med-di-dia.com), to focus on EU MedTech regulations and quality compliance requirements. The official launch was held in Galway on Monday 16th September 2019. We were delighted to welcome the Mayor of Galway, Councillor Mike Cubbard, who started our celebrations with a thoughtful and supportive speech. And talking about ‘support’, we’ve had such a warm welcome by the Galway Technology Centre (where the new office is), Galway City and Ireland as a whole. Everyone has been so helpful.
Cambridge 23September 2019:As the second cohort of Accelerate@Babraham start up competition winners begin their five-month programme, the Babraham Research Campus has confirmed a further injection of financial and mentoring support for the initiative from new sponsors LifeArc. The additional funding will bolster the ability of the Babraham Research Campus to drive innovation in early science within the Cambridge life science cluster.
AMSBIO has launched a range of ELISA Host Cell Protein (HCP) detection kits that allow you to detect the presence of host cell protein impurities in your therapeutic at any phase of your product development.
PredictImmune Announces New ‘Framework Agreement’ with Cambridge Enterprise to Allow Future Expansion of Original IP License to Expand its Commercial Product Pipeline; Extending the Benefits of Prognostic Testing to Include Systemic Lupus Erythematosus (SLE)
17 September 2019
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD) after a successful bid led by Eastern AHSN and Cambridge University Hospital Partners.
Cambridge, UK/MA, September 11 2019: o2h Discovery is pleased to announce multi FTE expansion to their synthetic chemistry collaboration with Cedilla Therapeutics, a Third Rock backed biotech company based in the Cambridge MA.
Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action.
In the latest of a string of senior appointments, Boyds, the leading consultancy business that supports the development of pharmaceutical and biotech products for patient benefit, has recruited Consultant Pharmaceutical Physician, Susan Tansey.
Dr Tansey joins Boyds with more than 20 years’ experience in rare disease clinical trials. A paediatrician specialising in respiratory paediatrics and neonatology, Susan joined the pharmaceutical industry in 1998 and has worked in clinical development across several therapeutic areas, including vaccine research.